Health ConditionsOveractive bladder (OAB) is a symptom-based syndrome defined by urinary urgency, frequency, and nocturia with or without urge incontinence. The International Continence Society (ICS) has standardized this definition, and OAB is characterised by urinary urgency, usually accompanied by increased daytime frequency and nocturia, with or without urgency urinary incontinence (UUI), in the absence of UTI or other identifiable pathology.
The current definition of OAB syndrome is a symptomatic diagnosis. In 1996, Abrams and Wein proposed a shift to a symptom-based definition, as it was clear that patients with bothersome symptoms did not always have detrusor overactivity (DO). The original terminology had its basis in pathophysiology, relying on the finding of non-volitional detrusor contractions during bladder filling, previously termed "detrusor instability" (idiopathic aetiology) or "detrusor hyper-reflexia" (neurogenic aetiology). The term currently recommended for this finding by the ICS is detrusor overactivity (DO).
OAB is accepted as an idiopathic disorder, diagnosed in the absence of other organic diseases. By definition it is "a disease of unknown cause," only diagnosed in the absence of other organic disease, such as cancer, neurological or structural abnormalities, or urinary tract infection. Despite this framing, there is a temptation to label OAB as "idiopathic" without obvious causation, given the poorly understood nature of its pathophysiology. OAB should instead be seen as a complex, multifactorial symptom syndrome, resulting from multiple potential pathophysiological mechanisms.
OAB is characterized by the presence of urinary urgency, and can be associated with incontinence, increased voiding frequency, and nocturia. Each of these components has a distinct clinical character:
OAB substantially reduces quality of life, increases the risk of depression and falls, and imposes a significant economic burden on healthcare systems.
A 2025 systematic review and meta-analysis encompassing 53 studies and 610,438 participants determined the global prevalence of OAB to be 20% (95% CI 0.18–0.21). Over the past 20 years, there has been an increase in OAB prevalence, rising from 18.1% to 23.9%. Among women, prevalence was 21.9%, indicating higher rates compared to men. The study also found higher prevalence rates among overweight and obese individuals (OR = 18.6) and those aged 60 years and above (OR = 28.3).
In adults aged over 40 years, OAB affects 9–43% of women and 7–27% of men, with women consistently showing higher prevalence. A survey of adults conducted in five countries demonstrated an overall prevalence of OAB symptoms of 12%.
OAB involves the bladder (specifically the detrusor muscle and urothelium), the urethra, and the urethral sphincter. The detrusor is a smooth muscle layer that contracts during voiding and must remain relaxed during filling. In OAB, this filling-phase quiescence is disrupted.
Three main factors have been proposed regarding the cause of OAB: myogenic, neurogenic, and urotheliogenic. Disturbance of any of the three factors, or a combination of these factors, can attribute to OAB.
The urothelium — the specialized epithelium lining the bladder — is no longer viewed purely as a passive barrier. It expresses receptors (including muscarinic, adrenergic, and transient receptor potential channels) and releases signaling molecules such as ATP and nitric oxide in response to stretch and chemical stimuli. Disruption of this sensory function is considered a key urotheliogenic driver of OAB.
A distinct neurogenic form of OAB arises from identifiable neurological disease. The prevalence and incidence of neurogenic OAB (nOAB) are poorly defined. A systematic review identified nOAB epidemiological data and estimated the incidence and prevalence of urinary incontinence and detrusor overactivity in patients with multiple sclerosis, spinal cord injury, Parkinson's disease, stroke, and spina bifida. Random-effect meta-analysis found the prevalence of urinary incontinence was 50.9% in patients with MS, 52.3% with spinal cord injury, 33.1% with Parkinson's disease, and 23.6% with stroke.
OAB syndrome is highly prevalent, and increasingly so with aging. Age-related changes in detrusor compliance, reduced bladder capacity, impaired central inhibitory control, and declining sex-hormone levels are all implicated.
A systematic review and meta-analysis that included 13 observational studies with 24,698 participants found that metabolic syndrome was associated with an increased risk of OAB. A cohort study following older adults for 5 years found that individuals with metabolic syndrome had a significantly higher incidence of OAB compared to those without it; the underlying mechanisms suggested involve insulin resistance, inflammation, and oxidative stress associated with metabolic syndrome.
Accumulated evidence suggests that MetS might contribute to the underlying mechanisms for developing OAB, and MetS-associated OAB could be a subtype of OAB. Based on results of animal studies and epidemiological observations, proposed common pathophysiologies between MetS and OAB include autonomic and peripheral neuropathies, chronic ischemia, proinflammatory status, and dysregulation of nutrient-sensing pathways such as insulin resistance.
Regarding obesity specifically: Obesity was identified as the only independent predictor for OAB (OR 1.09, 95% CI 1.05–1.13) and detrusor overactivity (OR 1.06, 95% CI 1.03–1.08) in a prospective cohort study of women with lower urinary tract symptoms. Central obesity is associated with increased pressure on the bladder, and fat tissue acts as a neuroendocrine organ that produces inflammatory factors and induces the sympathetic nervous system.
Low physical activity was the only direct risk factor linked prospectively to the onset of OAB (relative risk 2.47; 95% CI 1.82–3.36), in addition to older age. Poor lifestyle factors causally linked to diabetes and obesity may contribute to the onset of OAB; low physical activity appears to be an important modifiable causal factor for OAB, operating directly as well as indirectly via pathways involving obesity or diabetes.
Despite OAB being classified as idiopathic, a growing body of research provides evidence that a significant proportion of OAB patients have active bladder infection. Clinical studies find OAB patients are significantly more likely than control patients to have pathogenic bacteria in their urine and increased bladder inflammation. The evidence supports the concept that urinary tract infection may be an underappreciated contributor to the pathophysiology of some OAB patients.
Several other pathophysiological factors have been implicated in OAB, including metabolic syndrome, affective disorders, sex hormone deficiency, urinary microbiota, and gastrointestinal functional disorders.
The causative pathology of OAB is diverse, including bladder outlet obstruction (BOO), bladder ischemia, aging, metabolic syndrome, psychological stress, affective disorder, urinary microbiome, and localized and systemic inflammatory responses. In men, benign prostatic enlargement is a common contributor to BOO-induced OAB.
Scientific Evidence: An increased risk of overactive bladder and urinary incontinence was observed with vitamin D deficiency (OR = 4.46 for OAB; OR = 1.30 for urinary incontinence). Vitamin D levels were relatively low in patients with overactive bladder or urinary incontinence. On the basis of existing data, the risk of urinary incontinence was reduced by 66% after vitamin D supplementation (OR = 0.34; 95% CI 0.18–0.66; P = 0.001). Vitamin D deficiency increases the risk of OAB and urinary incontinence, and vitamin D supplementation reduces the risk of urinary incontinence, according to a 2023 systematic review and meta-analysis published in Nutrition Reviews.
However, a large-scale interventional study produced more mixed findings. An ancillary study evaluating vitamin D supplementation for preventing or treating OAB and urinary incontinence in men used data from VITAL (VITamin D and OmegA-3 TriaL), enrolling men aged ≥55 years. Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings.
A 2025 meta-analysis of RCTs found that out of an initial 301 articles, four RCTs from Iran, UK, and Turkey (2019–2023) were included, encompassing 263 participants. The meta-analysis on vitamin D's impact on UI severity initially showed a non-significant reduction, while after sensitivity analysis revealed a significant reduction. However, premenopausal women and urge UI specifically showed non-significant reductions. The notable heterogeneity among studies highlights the need for further research before clinical approval for high-dose vitamin D supplementation can be recommended.
Evidence strength: Observational data is consistent in showing lower vitamin D levels in OAB patients. Interventional RCT evidence is mixed and limited by small sample sizes and high heterogeneity. The association is biologically plausible via vitamin D's role in smooth muscle function and neurological regulation, but the relationship is not yet considered established for supplementation as a therapeutic intervention.
Scientific Evidence: Magnesium plays a role in smooth muscle relaxation and neuromuscular transmission, providing a plausible mechanistic basis for its investigation in OAB. Magnesium depletion may be an overlooked contributor to OAB, and maintaining optimal levels of specific nutrients including vitamin D and magnesium is essential for supporting muscle function, nerve signaling, and overall health. A study in Scientific Reports using NHANES (National Health and Nutrition Examination Survey) data found that those with higher signs of magnesium depletion had a notably increased risk of OAB.
Evidence strength: The available evidence for magnesium in OAB is primarily cross-sectional and observational. Robust RCTs specifically targeting magnesium supplementation in OAB remain limited. The mechanistic rationale — magnesium's role in inhibiting spontaneous detrusor contractions — is well-founded in physiology but clinical evidence is preliminary.
Traditional Use: Traditional use indicates that pumpkin seed (Cucurbita pepo L.) may be helpful in combating OAB symptoms. Pumpkin seeds have been used in indigenous North American and Central European traditions for urinary complaints, including those associated with the prostate and bladder. The seeds were consumed whole, as an oil, or as a decoction.
Scientific Evidence: One study evaluated the effect of pumpkin seed oil from Cucurbita maxima on urinary dysfunction in human OAB. Forty-five subjects were enrolled, and an extract of pumpkin seed oil (10 g of oil/day) was orally administered for 12 weeks. The extract of the seed is a rich source of vitamins, linoleic acid, oleic acid, and microelements, and the oil extracted from Cucurbita pepo has been useful for the treatment of urinary disorders. The authors noted that results were preliminary and that further study is needed.
A more rigorous study examined a combination product: A randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of Cucuflavone (containing extracts of pumpkin seed and soy germ) in 120 subjects suffering from OAB. After 12 weeks, subjects taking Cucuflavone experienced a significant reduction versus baseline in urination frequency, urgency, incontinence frequency, maximum urgency score, nocturnal urination frequency, and OAB-symptom scale. The placebo group reached significant differences for frequency, incontinence, and OAB-symptom scale. No adverse events or abnormal changes in safety parameters occurred. Soy isoflavones (Glycine max) are well-documented for hormonal imbalance-related indications, which likely contributed to the combination's effect. Because this trial tested a combination product, the individual contribution of pumpkin seed extract versus soy germ extract cannot be disaggregated from the published results.
Evidence strength: Preliminary to moderate. A double-blind RCT exists, but sample sizes are small, one trial tested a combination product, and independent replication is limited. The available evidence is encouraging but insufficient to establish efficacy with confidence.
Traditional Use: Gosha-jinki-gan (GJG) is a traditional Chinese blended herbal medicine composed of 10 different herbs: Rehmanniae radix, Achyranthis radix, Corni fructus, Moutan cortex, Alismatis rhizome, Dioscorea rhizoma, Plantaginis semen, Hoelen, processed Aconiti tuber, and Cinnamomi cortex. It has been used in East Asian traditional medicine (Japanese Kampo and Traditional Chinese Medicine) for kidney deficiency patterns associated with urinary frequency and weakness.
Scientific Evidence — Preclinical: Gotoh and colleagues reported inhibition of activated spinal κ opioid receptors by GJG, with the inhibition of bladder sensation leading to decreased urinary frequency in rats. Suzuki and colleagues reported that bladder contraction mediated by pelvic nerve stimulation and induced by acetylcholine administration was significantly inhibited by GJG administration at 100 mg/kg, with effects similar to those seen with atropine at 0.1 mg.
Scientific Evidence — Human Studies: The efficacy and tolerability of a single-agent treatment with 7.5 g/day Gosha-jinki-gan in Japanese females with OAB were analyzed objectively. A total of 44 Japanese females diagnosed with OAB were enrolled. Before and after treatment, urinary frequency was measured and quality of life questionnaires administered. Total scores of International Prostate Symptom Score, quality of life index scores, and urinary frequency during the daytime and sleep were significantly decreased. Objective evaluation yielded a result of excellent in 7%, improved in 46%, unchanged in 41%, and worsened in 7%. Adverse reactions were observed in 9%.
In a study of elderly males with OAB: Gosha-jinki-gan, a traditional Chinese medicine, was evaluated for clinical OAB. GJG was administered for 6 weeks to elderly male patients with OAB to assess its efficacy and tolerability; 30 male patients with over 6 months of OAB symptoms received 2.5 g GJG mixture × 3/day, after which efficacy, safety, and tolerability were assessed. GJG was significantly effective in improving urgency, micturition frequency, nocturia, and urinary incontinence. However, maximum urinary flow, average flow, and post-void residual did not significantly change. Mild adverse effects were observed in 3 cases, consisting of diarrhea, nausea, and urinary frequency.
Evidence strength: Early-phase clinical evidence from small, mostly uncontrolled or open-label studies in Japanese populations. Mechanistic data from animal models is supportive. Large-scale RCTs are lacking. Evidence is preliminary but with a plausible neurological mechanism.
Traditional Use: The medicinal benefits of Ganoderma lucidum have been widely recognized for thousands of years in East Asia, mainly in China, Japan, and Korea. Its fruiting body is called "Reishi" in Japan and "líng zhī" in China. Traditionally, it is known as a "longevity-promoting tonic" and has been used in China for Qi replenishment, mind relaxation, and easing cough and asthma.
Scientific Evidence: To evaluate the safety and efficacy of a G. lucidum extract that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms, a double-blind, placebo-controlled, randomized dose-ranging study was conducted in men with lower urinary tract symptoms (LUTS). 88 men over the age of 49 years with slight-to-moderate LUTS were randomly assigned to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. G. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at end of treatment (mean difference −1.18 points; 95% CI −1.74 to −0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, or prostate volume. Overall treatment was well tolerated with no severe adverse effects. The extract of G. lucidum was well tolerated and improved IPSS scores.
Evidence strength: One well-designed double-blind RCT with a modest effect on symptom scores in men with LUTS; the study was specifically conducted in a population with prostatic contributions to LUTS rather than pure idiopathic OAB. Effects on pure OAB in women are not established. Evidence is preliminary.
Traditional Use: Corn silk — the thread-like stigmas of the maize plant — has been used in traditional herbal medicine across Indigenous American, Chinese, and European traditions for urinary complaints including painful urination, urinary frequency, and cystitis. Preparations have historically included teas and decoctions from the dried stigmas.
Scientific Evidence: Corn silk (Zea mays) is listed among herbal supplements studied in relation to OAB in a peer-reviewed PMC review of herbal supplements for OAB. However, controlled clinical trial data in humans specifically for OAB is not currently established in the peer-reviewed literature reviewed here.
Evidence strength: Traditional use is well-documented historically, but rigorous clinical evidence for OAB specifically is absent. Animal and in-vitro models have been studied for diuretic and anti-inflammatory properties, but these do not constitute evidence of efficacy in human OAB.
Traditional Use: Buchu leaf originates from the Western Cape of South Africa and has been used by the indigenous Khoikhoi and San peoples, as well as adopted by European settlers, for urinary tract conditions. It was listed in the United States Pharmacopoeia in the 19th century for urinary disorders.
Scientific Evidence: Buchu leaf was popular in 19th-century America for urinary conditions but has zero clinical trials for OAB. A 2022 review concluded that health claims for buchu "need to be substantiated by randomized, double-blind and placebo-controlled studies."
Evidence strength: No controlled clinical trials for OAB exist as of the most recent literature. Traditional use is well-documented, but this does not constitute evidence of efficacy by current standards.
Traditional Use: Fermented and whole soy foods have been a dietary staple in East Asian cultures for millennia. Soy isoflavones act as phytoestrogens and have been investigated for conditions related to estrogen deficiency, including urinary symptoms in postmenopausal women.
Scientific Evidence: Soy isoflavones (Glycine max) are well-documented for hormonal imbalance-related indications. As described above in the pumpkin seed section, a randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of a combination of pumpkin seed extract and soy germ extract in 120 subjects with OAB, with significant reductions in OAB symptom measures after 12 weeks. Because the trial used a combination product, the independent contribution of soy isoflavones cannot be isolated from this data alone.
Evidence strength: Preliminary, as part of a combination product in one RCT. Independent RCT evidence for soy isoflavones alone in OAB is not established in the currently available literature.
Caffeine reduction was statistically effective for urgency symptoms. Frequency was assessed in 5 studies, which showed decreasing caffeine and fluid intake was effective in treating the symptoms, according to a 2023 systematic review of 8 studies. Caffeine reduction was statistically effective for urgency symptoms, but increasing fluid intake was not. Restricting caffeine intake was effective in treating nocturia and urge incontinence episodes, but restricting both caffeine and fluid intake together was not.
According to previous studies, fluid intake may not influence the incident rate of urinary incontinence, but increased caffeine intake was likely to increase the number of urge incontinence episodes. Hence, there was no need to reduce fluid intake to control incontinence, but reducing caffeine was helpful.
Caffeine is understood to act as a direct stimulant of detrusor muscle contractility and also exerts a diuretic effect by inhibiting renal tubular reabsorption of water and sodium. Both mechanisms may contribute to urgency and frequency symptoms.
The National Institute for Health and Care Excellence (NICE) guideline suggested that women with urinary incontinence could modify their fluid intake as high or low, but did not indicate the applicable methods for each subtype of urinary incontinence in detail. The systematic review evidence suggests that both excessive and severely restricted fluid intake may worsen OAB symptoms — concentrated urine from under-hydration can irritate the urothelium, while excessive volumes increase voiding frequency. The evidence base for precise fluid intake recommendations in OAB remains limited.
Behavioral approaches are in part aimed at improving symptoms with patient education on healthy bladder habits and lifestyle modifications, including the establishment of normal voiding intervals, elimination of bladder irritants from the diet, management of fluid intake, weight control, management of bowel regularity, and smoking cessation. Commonly identified potential dietary bladder irritants include carbonated beverages, artificial sweeteners, citrus fruits, tomatoes, spicy foods, and alcohol, though the level of evidence for each is variable. Caffeine intake may elicit an irritative bladder, and is the dietary irritant with the most consistent evidence base.
Obesity was the only independent predictor for OAB and detrusor overactivity in women with lower urinary tract symptoms. The study demonstrated a correlation between obesity and OAB/DO in female patients. However, other components of metabolic syndrome did not appear to be associated with either OAB or DO. Weight reduction should be strongly recommended in women with OAB. Addressing the individual components of metabolic syndrome, such as obesity, hypertension, and dyslipidaemia, may be important in managing the progression of OAB.
Low physical activity was the only direct risk factor linked prospectively to the onset of OAB (RR 2.47; 95% CI 1.82–3.36), in addition to older age. Poor lifestyle factors causally linked to diabetes and obesity may contribute to the onset of OAB; low physical activity appears to be an important modifiable causal factor for OAB operating directly as well as indirectly via pathways involving obesity or diabetes.
The first-line conservative approach to the symptoms of OAB includes behavioral interventions, which consist of strategies that modify lifestyle, life habits, and patient environment, with scheduled voiding regimens including bladder training (BT) and pelvic floor muscle training (PFMT). BT has been shown to be important not only for results but because it has low cost, low complexity, and reduced side effects.
Bladder training in people with OAB helps to control urgency by diverting attention (e.g. performing mental arithmetic or pelvic floor muscle contractions) and helping them to relax (e.g. with deep breathing activities), and gradually prolonging the voiding interval by 15 minutes. Eventually, the patient may be able to void every three to four hours without the frequent urge to urinate.
Training techniques include bladder training, which includes a progressive voiding schedule together with relaxation and distraction for urgency suppression, and multicomponent behavioural training, which, in conjunction with pelvic floor muscle exercises, includes PFM contraction to control urgency and increase the interval between voids.
Constipation and straining are identified in clinical guidelines as bladder irritants and contributors to pelvic floor dysfunction. Increasing fiber intake through fruits and vegetables to reduce constipation, with adequate hydration to make stools softer and easier to pass, is included in behavioral modification protocols for OAB.
Healthy bladder habits include lifestyle modifications including eliminating bladder irritants from the diet, managing fluid intake, weight control, managing bowel regularity, and smoking cessation. Tobacco smoke constituents and chronic cough associated with smoking are hypothesized to exacerbate OAB symptoms and pelvic floor dysfunction.
The evidence base for nutritional and natural-health interventions in OAB can be characterized as follows:
OAB should be seen as a complex, multifactorial symptom syndrome, resulting from multiple potential pathophysiological mechanisms, and nutritional and lifestyle research should be interpreted within that framework. No nutritional intervention currently carries the same quality of evidence as established behavioral and pharmacological therapies.
Beta-sitosterol is a plant sterol with systematic review evidence for reducing BPH-related urinary symptoms that overlap significantly with OAB, including urgency, frequency, and nocturia. A systematic review of 4 RCTs (n=519 men) found beta-sitosterol improved symptom scores by 4.9 points and peak urinary flow by 3.9 mL/s versus placebo. A 2024 RCT of beta-sitosterol–enriched saw palmetto showed significantly lower Overactive Bladder Symptom Scores.
Capsaicin, the active compound from chili peppers, acts on bladder TRPV1 (vanilloid) receptors on afferent nerves. Intravesical capsaicin instillation desensitizes C-fiber afferents, inhibiting the micturition reflex and increasing bladder capacity. It is reviewed in both the PMC Reviews in Urology (2013) and a 2024 PMC comprehensive OAB review as a recognized intervention for neurogenic detrusor overactivity; however, intravesical application causes local irritation, limiting use.
Intravesical capsaicin has been clinically tested for overactive bladder and neurogenic detrusor overactivity, with evidence of amelioration of urinary frequency and incontinence through TRPV1-mediated C-fiber desensitization. Results are mechanistically well-grounded and supported by human clinical studies.
Open non-randomized clinical studies indicate goldenrod can reduce urgency and painful urination in overactive bladder within 2–4 weeks. In one study of 512 people with chronic overactive bladder taking 425 mg of dry goldenrod extract three times daily, 96% reported improvement. Antispasmodic effects on bladder smooth muscle have been documented in pharmacological research.
Horsetail (Equisetum arvense) is one of the oldest herbal remedies for urinary complaints, traditionally used since ancient Roman and Greek times. As part of the Urox combination (with Crataeva nurvala and Lindera aggregata), it was tested in a phase 2 randomized, double-blind, placebo-controlled trial (n=150) that showed significantly reduced urinary frequency, nocturia, urgency, and incontinence at 8 weeks. The Reviews in Urology (PMC) identified horsetail as one of the key herbal agents studied for OAB.
Magnesium depletion is significantly associated with overactive bladder in large population-based data (NHANES 2005–2018, n=28,621). Mechanistically, magnesium acts as a natural calcium antagonist, and deficiency leads to excess calcium influx causing involuntary detrusor contractions characteristic of OAB. An early clinical study also found magnesium supplementation had a positive effect on urinary frequency, urgency, and voiding difficulty.
Nettle root extract has been studied in RCTs for lower urinary tract symptoms including urinary urgency, frequency, nocturia, and incomplete bladder emptying—the hallmark features of overactive bladder. Products containing nettle root are specifically recommended for symptomatic treatment of urinary incontinence and frequency. The clinical trial database includes conditions directly overlapping with OAB symptom clusters.
Pumpkin seed oil and extract have direct clinical trial evidence for OAB. A 2014 randomized, double-blind, placebo-controlled trial (n=120) of a pumpkin seed and soy germ extract combination found significant reductions in urination frequency, urgency, incontinence, and nocturia versus placebo. An open-label study of 10 g/day pumpkin seed oil over 12 weeks also improved Overactive Bladder Symptom Scores. Pumpkin seed (Cucurbita pepo) is officially ESCOP-monographed for irritable bladder and BPH-related urinary symptoms.
Quercetin is a flavonoid with anti-inflammatory properties shown to benefit bladder pain and interstitial cystitis (IC), conditions that overlap with OAB. A clinical trial (Katske et al., Tech Urol 2001) found quercetin supplementation improved IC symptoms at 4 weeks. Naturopathic guidelines reference quercetin for bladder inflammation underlying OAB. However, no placebo-controlled RCT has tested quercetin as a standalone treatment specifically for OAB.
Reishi mushroom (Ganoderma lucidum) has been formally tested in a randomized, double-blind, placebo-controlled trial (n=88 men) for lower urinary tract symptoms. Treatment with 6 mg/day of G. lucidum extract for 12 weeks produced significantly better International Prostate Symptom Score improvement versus placebo (mean difference −1.18 points; P<0.0001). G. lucidum also shows potent 5α-reductase inhibitory activity, reducing prostate-driven bladder overactivity.
Saw palmetto berry extract (320 mg/day) has been evaluated in clinical trials for OAB-related urinary symptoms in both men and women. A 2020 RCT in 44 men and a 2022 multicenter RCT in 75 women both reported significant reductions in daytime frequency, urgency, and nocturia on the Overactive Bladder Symptom Score. A 2024 Cochrane review found limited overall benefit for BPH, but saw palmetto shows specific OAB-pathway activity via muscarinic and vanilloid receptor binding.
Soy isoflavones (primarily genistein and daidzein) have been studied for OAB via multiple mechanisms. A 2014 RCT (n=120) of a pumpkin seed + soy germ extract combination significantly reduced urination frequency, urgency, and nocturia versus placebo. A cross-sectional study of 2,000 elderly Chinese men found dietary soy isoflavone intake was linked to a lower risk of lower urinary tract symptoms. In vitro, genistein and daidzein dose-dependently decrease detrusor contractions.
Vitamin D deficiency is strongly linked to OAB, with a meta-analysis (PubMed PMID 37195440) finding vitamin D–deficient individuals had more than 4-fold higher odds of OAB and 30% higher odds of urinary incontinence. Vitamin D supplementation reduced urinary incontinence risk by 66% in the same meta-analysis. Vitamin D receptors are present in bladder muscle and pelvic floor tissue, and clinical supplementation has been shown to improve urinary symptoms.
Vitamin D3 (cholecalciferol) is the primary supplemental form studied in relation to overactive bladder and urinary incontinence. A meta-analysis found vitamin D deficiency increased OAB risk more than 4-fold, and supplementation reduced urinary incontinence risk by 66%. Vitamin D3 receptors exist in bladder muscle and pelvic floor tissue, and correcting deficiency has shown clinical urinary symptom improvements.
Go back